TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales

Teva Pharmaceutical Industries (TEVA) reported Q2 adjusted earnings of $0.66 per share, exceeding consensus, but revenues of $4.18 billion missed estimates, flat year-over-year. While strong growth in branded drugs like Ajovy, Austedo, and Uzedy drove U.S. sales, this was largely offset by declines in generic revenues and the exit from Japan. Despite the revenue miss, Teva reaffirmed its 2025 total revenue guidance and raised the outlook for its key branded portfolio and adjusted EPS, underscoring its strategic pivot towards higher-margin products and new biosimilar launches, even as its shares have significantly underperformed the industry year-to-date.

Analysis

Teva Pharmaceutical's second-quarter 2025 results present a mixed but strategically coherent picture. The company reported adjusted EPS of $0.66, beating consensus by $0.03, driven by improved profitability. However, revenues of $4.18 billion missed expectations and remained flat year-over-year, illustrating the core challenge of its ongoing business transition. The positive momentum stems from its branded drug portfolio, where Austedo, Ajovy, and Uzedy delivered impressive year-over-year sales growth of 22%, 53%, and 120%, respectively. This growth, however, was offset by a 6% decline in U.S. generic revenues and a 17% drop in International Markets sales, the latter primarily due to the divestment of its Japanese business. Despite the top-line miss, the strategic shift towards higher-value products is proving effective for margins; adjusted gross margin expanded by 170 basis points to 54.6% and adjusted operating margin grew 180 basis points to 27.1%. Management's confidence is reflected in the upwardly revised full-year 2025 guidance for its key branded drugs and adjusted EPS, signaling a belief that margin expansion will continue to drive bottom-line outperformance even as the top-line stabilizes. The significant year-to-date stock plunge of 23.6%, which starkly underperforms the industry's 9.8% decline, suggests that the market remains skeptical or is awaiting more definitive evidence that new biosimilar launches can successfully reinvigorate the generics segment.

Key Decisions for Investors

• Investors should monitor the sales trajectory of key branded drugs Austedo, Ajovy, and Uzedy against their newly raised guidance, as their continued outperformance is critical to validating the company's pivot and margin expansion story.
• Closely track the initial market uptake and revenue contribution from new biosimilar launches Simlandi and Selarsdi, as their success is essential for stabilizing the declining generics segment and providing a future growth pillar.
• Given the significant stock underperformance relative to positive operational developments like margin growth and raised EPS guidance, consider whether current levels present a value opportunity, while remaining cautious of the persistent top-line headwinds and negative market sentiment.
• Use the company's progress toward its 30% adjusted operating margin target for 2027 as a key long-term metric to evaluate the ultimate success of the turnaround strategy.